NCT01822691

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

A Phase II Study to Determine the Safety and Efficacy of INCB024360 in Patients With Myelodysplastic Syndromes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this research study is to assess whether the participant's disease, Myelodysplastic Syndromes (MDS), responds favorably to INCB024360. The study will also evaluate the long-term outcomes of the participant's disease after they have finished taking INCB024360.

Conditions

• Myelodysplastic Syndromes

Interventions

Type	Name	Description
DRUG	INCB024360	INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.

Timeline

• Start date: 2013-07-01
• Primary completion: 2015-01-01
• Completion: 2015-02-01
• First posted: 2013-04-02
• Last updated: 2016-01-18
• Results posted: 2016-01-18

Locations

1 site across 1 country: United States